M2 Pharma - Therapy Areas

LifeMax Receives Rare Pediatric Disease Designation for LM-030 for the Treatment of Netherton Syndrome

19 July 2019 - - The US Food and Drug Administration granted rare pediatric disease designation to LM-030, an investigational therapy licensed from Swiss drugmaker Novartis and ready to enter into piv...

First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder

17 July 2019 - - US-based biotechnology company Axial Biotherapeutics has dosed the first patient in its Phase 1b/2a clinical trial of AB-2004. In animal models, AB-2004 has demonstrated the ability t...

Dr. Reddy's Launches Over-the-Counter Store Brand Equivalent of Mucinex D Extended Release Tablets in Two Strengths in the US Market

12 July 2019 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched an over-the-counter store-brand equivalent of Mucinex D Extended Release Tabl...

CEL-SCI Collaborators Presents Data for New Vaccine in the Treatment of Rheumatoid Arthritis at the International Conference on Immunity and Immunochemistry Meeting

11 July 2019 - - One of US-based drug and vaccine developer CEL-SCI Corp.'s (NYSE American: CVM) key collaborators from Rush University Medical center, Dr. Adrienn Markovitz, an assista...

First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

3 July 2019 - - The first patient has been enrolled in the Phase 1b/2 clinical study of VE416 in adults and adolescents with a history of peanut allergy, US-based clinical-stage company Vedanta Biosci...

Vedanta enrols first patient in Phase 1b/2 clinical study of VE416

3 July 2019 - Vedanta Biosciences, a subsidiary of PureTech Health, has enrolled its first patient in the Phase 1b/2 clinical study of VE416 in adults and adolescents with a history of peanut allergy,...